🟢 MRNA is trading 3.16% up today driven by mRNA-1010 flu vaccine regulatory filings

MRNA is trading at $31.84 (+3.16%) following the announcement of global regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010.

• The company filed for marketing authorization with the FDA, EMA, Health Canada, and Australia's TGA on January 5, 2026.
• Phase 3 efficacy data demonstrated superiority over standard-dose flu vaccines, achieving 26.6% relative vaccine efficacy across adults 50+ and 27.4% in those 65+.
• This represents a major milestone for Moderna's respiratory portfolio, positioning potential product launches in 2027.